Dihexa
HGF/c-Met nootropic. Dihexa is not FDA approved for any use.
Key facts
- Class
- HGF/c-Met nootropic
- Also called
- No common aliases
- Half-life
- Not found
- No published half-life found (PubMed search, 11 Oct 2026)
- FDA status
- Not approved
- Off Category 2, 15 Apr 2026
- PCAC vote
- Not reviewed
- not on the Jul 2026 PCAC agenda
- WADA
- Unclear
- Not named on the 2026 list
Dihexa guides
Evidence at a glance
Human and animal counts are PubMed records from our evidence ledger (search counts, not studies we reviewed). The grade is the strongest design among the studies we summarised for that goal: a human randomized trial outweighs any number of animal studies.
| Condition | Human studies | Animal studies | Studies we summarised | Evidence grade |
|---|---|---|---|---|
| Cognition | Not in our ledger | Not in our ledger | 3 | Animal evidence, 2 of 4Journal of Huntington's disease 2024, PMID 38489193 |
Grades follow our evidence scale. Summarised studies come from our evidence file, each quote checked against the abstract or label.
An angiotensin IV derivative built to survive the gut and enter the brain
The paper that introduced dihexa describes chemical modifications of angiotensin IV analogs that produced an orally active, brain-penetrant, metabolically stabilized compound.[11]
In an APP/PS1 Alzheimer mouse model, it restored spatial learning in the Morris water maze. This is mouse work only.[12]
Animal results are not uniformly positive
In a rat model of Huntington-like symptoms, an angiotensin IV analog coded PNB-0408 did not protect against the neurotoxin-induced deficits.[5]
In zebrafish larvae, a Dihexa concentration of 1 μM gave the best protection of lateral-line hair cells from ototoxins.[13]
In a rat nerve-repair study, motor function improved when stem cells were paired with Dihexa injected into the muscle. This animal result does not isolate dihexa alone.[14]
Regulatory path
No FDA-approved dihexa product exists in the Drugs@FDA search.[3]
FDA removed dihexa acetate from category 2 after the nomination was withdrawn, and said it intends to consult its advisory committee before the end of February 2027.[4]
WADA does not name dihexa; its S0 catch-all covers substances with no health-authority approval.[2]
Common questions
Is Dihexa FDA approved?
No. Dihexa is not FDA approved for any use. The FDA removed it from Category 2 on 15 Apr 2026.
What is dihexa?
A synthetic analog of angiotensin IV, studied in rodents for cognition.[11]
What does dihexa do?
In an Alzheimer mouse model it restored spatial learning; no human study has been found.[12]
Is there oral dihexa?
The founding rat paper describes it as orally active; no human oral data exist in the cached literature.[11]
Sources
- 1Certain bulk drug substances for use in compounding that may present significant safety risks (Category 2; 'nominated but withdrawn' table, content current as of 22 Apr 2026)U.S. Food and Drug Administration · 2026fda.govAccessed 2 Oct 2026
- 2World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
- 3United States: No FDA-approved product found: Drugs@FDA (openFDA) search for active ingredient "dihexa" returned no matches on 2 Oct 2026.U.S. Food and Drug Administration · 2026api.fda.govAccessed 2 Oct 2026
- 4US compounding: Dihexa acetate was removed from FDA's 503A category 2 after the nominator withdrew; FDA announced a PCAC consultation before the end of February 2027.U.S. Food and Drug Administration · 2026fda.govAccessed 2 Oct 2026
- 5Effects of an Angiotensin IV Analog on 3-Nitropropionic Acid-Induced Huntington's Disease-Like Symptoms in Rats.Journal of Huntington's disease · 2024PMID 38489193Accessed 2 Oct 2026
- 6PubMed search: dihexa[tiab] OR "N-hexanoic-Tyr-Ile-(6) aminohexanoic amide"[tiab] (17 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 7PubMed search: "N-hexanoic-Tyr-Ile-(6) aminohexanoic amide"[tiab] OR "Nle1-angiotensin IV"[tiab] OR "angiotensin IV analog"[tiab] OR "AngIV analog"[tiab] (14 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 8PubMed search: (dihexa[tiab] OR "hepatocyte growth factor"[tiab]) AND (mimetic[tiab] OR "angiotensin IV"[tiab] OR Nle[tiab]) AND (memory[tiab] OR cognit*[tiab]) (7 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 9FDA gives notice that 12 peptides will be removed from Category 2 (nominations withdrawn)FDA · 2026fda.govAccessed 2 Oct 2026
- 10PubMed search: (dihexa[tiab] OR "angiotensin IV analog"[tiab]) AND (adverse[tiab] OR "side effect*"[tiab] OR safety[tiab] OR tolerab*[tiab] OR toxicity[tiab] OR "case report"[pt]) (2 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
- 11Evaluation of metabolically stabilized angiotensin IV analogs as procognitive/antidementia agents.The Journal of pharmacology and experimental therapeutics · 2013PMID 23055539Accessed 2 Oct 2026
- 12AngIV-Analog Dihexa Rescues Cognitive Impairment and Recovers Memory in the APP/PS1 Mouse via the PI3K/AKT Signaling Pathway.Brain sciences · 2021PMID 34827486Accessed 2 Oct 2026
- 13Hepatocyte growth factor mimetic protects lateral line hair cells from aminoglycoside exposure.Frontiers in cellular neuroscience · 2015PMID 25674052Accessed 2 Oct 2026
- 14Stem cell, Granulocyte-Colony Stimulating Factor and/or Dihexa to promote limb function recovery in a rat sciatic nerve damage-repair model: Experimental animal studies.Annals of medicine and surgery (2012) · 2021PMID 34703584Accessed 2 Oct 2026
Found an error? Report a correction.